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ABSTRACT
Objectives: To evaluate different methods of reporting
response to treatment or disease status for their ability to
discriminate between active therapy and placebo, or to
reflect structural progression or patient satisfaction with
treatment using an exploratory analysis of the Abatacept
in Inadequate Responders to Methotrexate (AIM) trial.
Methods: 424 active (abatacept ,10 mg/kg) and 214
placebo-treated patients with rheumatoid arthritis (RA)
were evaluated. Methods of reporting included: (1)
response (American College of Rheumatology (ACR)
criteria) versus state (disease activity score in 28 joints
(DAS28) criteria); (2) stringency (ACR20 vs 50 vs 70;
moderate disease activity state (MDAS; DAS28 ,5.1) vs
low disease activity state (LDAS; DAS28 (3.2) vs
DAS28-defined remission (DAS28 ,2.6)); (3) time to
onset (time to first ACR50/LDAS) and (4) sustainability of
ACR50/LDAS for consecutive visits. Methods were
assessed according to: (1) discriminatory capacity
(number of patients needed to study (NNS)); (2)
structural progression (Genant-modified Sharp score) and
(3) patient satisfaction with treatment. Positive likelihood
ratios (LR) evaluated the ability of the above methods to
reflect structural damage and patient satisfaction.
Results: MDAS and ACR20 had the highest discrimina-
tory capacity (NNS 49 and 69). Sustained LDAS best
reflected no radiographic progression (positive LR >2).
More stringent criteria (at least ACR50/LDAS), faster
onset ((3 months) and sustainability (.3 visits) of
ACR50/LDAS best reflected patient satisfaction (positive
LR .10).
Conclusions: The optimal method for reporting a
measure of disease activity may differ depending on the
outcome of interest. Time to onset and sustainability can
be important factors when evaluating treatment response
and disease status in patients with RA.
The current gold standard composite assessment
used in clinical trials of patients with rheumatoid
arthritis (RA) is the American College of
Rheumatology (ACR) criteria, evaluated at study
endpoint. Increasingly, the disease activity score in
28 joints (DAS28) is also used.
1 Different methods
can be used to report these composite indices: (1)
response to treatment (eg, ACR criteria) versus
disease state (DAS28 criteria); (2) ‘‘stringent’’
versus ‘‘less stringent’’ assessment (eg, ACR70
versus ACR20); (3) time to onset of a successful
response (eg, time to achievement of ACR50) or (4)
sustainability of a response (eg, maintenance of an
ACR50 over a given period of time).
To evaluate the performance of these methods,
several different perspectives may be considered:
those of the clinical trial investigator, the rheuma-
tologist and the patient. For example, the trial
investigator seeks to reduce the costs and risks
associated with trial design by determining the
discriminatory capacity of specific reporting meth-
ods. Primarily, this may be achieved by reducing
the number of patients needed to study (NNS) to
discriminate between active drug and placebo. In
order to prevent irreversible loss of physical
function, one of the rheumatologist’s primary aims
is to inhibit structural damage, as assessed by
scores including the Sharp score
2 and its modifica-
tions.
3 Finally, patients are concerned with the
impact of their condition on daily life, including
dimensions such as quality of care. All three groups
are concerned with efficacy, safety, sustainability
of response to treatment or disease activity status.
The performance of different methods of report-
ing ACR and DAS28-based criteria according to the
different viewpoints or perspectives described
above has not previously been studied in a single
patient cohort. To address this, we used data from
the phase III, Abatacept in Inadequate Responders
to Methotrexate (AIM) trial in patients with RA.
The efficacy and safety results from this trial have
been reported elsewhere, using prespecified pri-
mary and secondary endpoints.
4 The objective of
the present exploratory analysis was to evaluate
different methods of reporting ACR and DAS28-
based criteria for their ability to discriminate
between active and inactive drugs, to reflect the
absence of structural damage progression or to
reflect whether patients are satisfied with their
treatment. Whereas a range of additional methods
is also currently used to assess clinical efficacy,
45
exhaustive assessment of all of these measures is
beyond the scope of this publication and we have
focused on the most commonly used composite
indices in clinical trials. To simplify the outputs of
this analysis further, presentation of data relating
to onset and sustainability have been limited to
ACR50 and low disease activity state (LDAS;
DAS28 (3.2).
METHODS
Database
The analyses reported here were exploratory
assessments of a global, phase III, 1-year, multi-
national, randomised, double-blind, placebo con-
trolled study of abatacept compared with placebo
(2 : 1) in combination with methotrexate in
Extended report
484 Ann Rheum Dis 2009;68:484–489. doi:10.1136/ard.2008.092577patients with active RA and an inadequate response to
methotrexate (clinical trials registration number
NCT00048568). The detailed study design of this trial has been
reported previously.
6
Methodology
General considerations
For these exploratory analyses, abatacept was considered the
‘‘active’’ drug and placebo the ‘‘inactive’’ drug. The sample size
was based on primary efficacy analyses.
6 The analyses presented
here are considered exploratory, as they were not prespecified
and the sample size may not be appropriate for statistical
testing. Because of the nature of this analysis, the imputation of
missing data was not appropriate; all analyses are based on
patients with data available at the visit of interest (‘‘as-
observed’’).
Assessments
Disease activity
The following composite indices were assessed on each visit day
before study drug administration for a duration of 6 months, at
week 2, week 4 and every 4 weeks thereafter: response to
treatment, ACR criteria
78(ACR20, 50 and 70) and status of
disease, DAS28 criteria (moderate disease activity state
(MDAS); DAS28 ,5.1), LDAS (DAS28 (3.2) and DAS28-
defined remission (DAS28 ,2.6)).
Methods of reporting ACR and DAS28 criteria
Response to treatment versus status of disease
To determine the performance of measures that assess response
to treatment versus those that assess disease status, the
proportion of patients achieving an ACR response or DAS28
status was compared at 6 months.
‘‘Stringent’’ versus ‘‘less stringent’’ methods
For the ACR criteria, ACR20 was regarded as ‘‘less stringent’’,
ACR50 as ‘‘intermediate’’ and ACR70 as ‘‘stringent’’. For
DAS28, MDAS was considered as ‘‘less stringent’’, LDAS was
considered ‘‘intermediate’’ and DAS28-defined remission was
considered ‘‘stringent’’. Assessments were performed at the end
of a 6-month study period.
Based on the results obtained in the above analyses
(comparing response versus status and ‘‘more stringent’’ versus
‘‘less stringent’’ methods), results for onset and durability were
only reported for ACR50 and LDAS, as these measures were of
comparable stringency and numbers of responders were high
enough to enable meaningful interpretation of the results.
Onset of action
To determine the importance of onset of action, the proportion
of patients achieving a first ACR50 response or LDAS within
1 month, or within the first 2, 3, 4, 5 or 6 months of the
evaluation period was assessed.
Sustainability of response or status of disease
To determine the importance of sustainability of a response/
status, the proportion of patients experiencing ACR50 or LDAS
for at least one, two, three, four, five or six consecutive visits
over 6 months of the evaluation period was calculated. Equal
weighting was applied for each visit.
Assessment of the different methods of reporting ACR response and
DAS28-derived criteria
Discriminatory capacity as assessed by NNS
Discriminatory capacity was calculated based on the number of
patients required per treatment arm to perform a two-arm 1 : 1
randomised study comparing active treatment with placebo,
based on a difference similar to that observed in the AIM study.
The number of patients required was calculated with the
appropriate basic testing procedure (with a = 0.05 (two-
tailed), b = 0.20, x
2 test for binary variables and Student’s t
test for continuous variables). The lowest NNS indicates the
greatest discriminatory capacity.
Structural damage and patient satisfaction
Structural damage progression in the hands and feet was
assessed as radiographic changes from baseline to year 1, using
Genant-modified Sharp scores.
39 The maximum possible
normalised total score (TS) was 290. Data were dichotomised
as the percentage of progressors (TS >0) versus non-progressors
(TS ,0).
Patient satisfaction with treatment was assessed at month 6
or at early termination
10 using the following question on a five-
point scale: ‘‘how would you rate your satisfaction with the
treatment you received?’’: excellent, 1; very good, 2; good, 3;
fair, 4; or poor, 5. Responses were dichotomisd as follows: 1, 2, 3
(favourable) versus 4, 5 (not favourable). A sensitivity analysis
was performed using different cut-offs for dichotomization
Table 1 Performance of ‘‘stringent’’ versus ‘‘less stringent’’ methods of reporting ACR (treatment response) and DAS28 (disease status) criteria
according to their discriminatory capacity and their ability to reflect inhibition of structural damage progression or patient satisfaction
Technique Less stringent Intermediate Stringent
ACR-based techniques at month 6 ACR20 ACR50 ACR70
Overall success, n/N (%) 373/576 (65) 205/576 (36) 98/576 (17)
NNS*, n 69 76 125
Structural damage at year 1{,L R + (95% CI) 1.11 (0.96 to 1.29) 1.22 (0.93 to 1.60) 1.18 (0.75 to 1.87)
Patient satisfaction at month 6{,L R + (95% CI) 2.79 (1.92, 4.05) Infinite Infinite
DAS28-based techniques at month 6 MDAS LDAS Remission
Overall success, n/N (%) 439/629 (70) 147/629 (23) 68/629 (11)
NNS*, n 49 71 103
Structural damage at year 11,L R + (95% CI) 1.20 (1.07 to 1.34) 1.48 (1.06 to 2.06) 1.71 (1.02 to 2.87)
Patient satisfaction at month 6",L R + (95% CI) 2.09 (1.64 to 2.65) 16.82 (4.23 to 66.94) Infinite
The total number of patients for each analysis was: *n = 636; {n = 551; {n = 575; 1n = 602; "n = 623. A lower number of patients needed to study (NNS) value indicates
greater discriminatory capacity; higher positive likelihood ratio (LR+) values indicate a greater probability of observing no structural damage or satisfaction with treatment.
Abatacept and placebo treatment groups were pooled for radiographic progression and patient satisfaction and unpooled for NNS. ACR, American College of Rheumatology; DAS28,
disease activity score in 28 joints; MDAS, moderate disease activity state (DAS28 (C-reactive protein; CRP) ,5.1); LDAS, low disease activity state (DAS28 (CRP) (3.2);
remission, DAS28 (CRP) ,2.6.
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Ann Rheum Dis 2009;68:484–489. doi:10.1136/ard.2008.092577 485(1, 2, (favourable) vs 3, 4, 5 (not favourable)); results were not
affected by cut-off choice (data not shown).
To evaluate the relevance of the different reporting techni-
ques for ability to reflect the inhibition of structural damage
progression and patient satisfaction, positive likelihood ratios
(LR)
11 were calculated. Available abatacept and placebo data for
patients in the AIM trial were pooled at each time point (as-
observed analysis). An LR determines the likelihood of a given
clinical finding in a patient with a studied disorder compared
with that in a patient without the studied disorder.
12 The LR,
which combines information on sensitivity and specificity, is
used to select the best and most appropriate diagnostic tests. LR
may range from 0 to infinity. An LR greater than 1 indicates an
increased probability that the target disorder is present and an
LR less than 1 indicates a decreased probability that the target
disorder is present. Likelihood ratios of 2, 5 and 10 increase the
probability of the studied disorder by approximately 15%, 30%
and 45%, respectively.
12 13 Based on the literature, a positive LR
greater than 2 may be considered of relevant prognostic value
and results will, therefore, be presented using this cut-off.
14 In
our study, the use of LR was transposed to express performance
of reporting techniques in reflecting structural damage or
patient satisfaction. Higher values are indicative of better
techniques. Although an infinite positive LR generally indicates
that a technique has good prognostic value, results should be
interpreted with caution when the proportion of patients
achieving success is low.
RESULTS
Patient disposition
In the 1-year AIM study, 433 and 219 patients were randomly
assigned and treated with abatacept or placebo, respectively, on
background methotrexate. In total, 385 (88.9%) and 162
(74.0%) patients in the abatacept and placebo groups, respec-
tively, completed 6 months of treatment and 375 (86.6%) and
158 (72.1%) patients were ongoing at 1 year. Baseline demo-
graphics and clinical characteristics, including disease activity,
were comparable between groups and are described elsewhere.
6
Patients from one site were excluded from efficacy analyses due
to compliance issues; 424 and 214 patients from the abatacept
and placebo groups, respectively, were included in the primary
efficacy analyses and were considered for this exploratory
analysis.
Treatment response and disease activity assessments
Overall, at month 6, 512 (80%) patients in the pooled abatacept
and placebo population reported satisfaction with treatment as
at least ‘‘good’’. At year 1, 97 (15%) patients in the pooled
abatacept and placebo population demonstrated no radio-
graphic damage progression from baseline (as defined by a
change in the TS ,0).
Response to treatment versus status of disease
The ability of ACR (response to treatment) versus DAS28
(disease status) either to detect a treatment effect (NNS) or to
reflect inhibition of structural damage progression or patient
satisfaction was generally comparable, when comparing meth-
ods of reporting with similar levels of stringency (table 1).
‘‘Stringent’’ versus ‘‘less stringent’’ methods of reporting
Table 1 presents the overall percentage of responders, NNS and
positive LR values for ‘‘less stringent’’ (ACR20 and MDAS),
‘‘intermediate’’ (LDAS or ACR50) and ‘‘stringent’’ (ACR70 or
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486 Ann Rheum Dis 2009;68:484–489. doi:10.1136/ard.2008.092577remission) criteria each evaluated with respect to the discrimi-
natory capacity (at month 6), radiographic progression (at year
1) and patient satisfaction (at month 6).
Using the NNS to determine discriminatory capacity, there
was a trend towards greater diagnostic ability with ‘‘less
stringent’’ versus ‘‘stringent’’ criteria (table 1). However,
interestingly, the NNS for ACR20 and ACR50 were similar.
No difference was observed between ‘‘less stringent’’, ‘‘inter-
mediate’’ and ‘‘stringent’’ methods of reporting ACR and
DAS28-based criteria in their ability to reflect inhibition of
structural progression (table 1) and all methods of reporting had
a positive LR of less than 2.
For patient satisfaction, positive LR were higher with the
‘‘stringent’’ and ‘‘intermediate’’ compared with ‘‘less stringent’’
criteria, suggesting that more stringent criteria better reflected
patient satisfaction with treatment (table 1).
Similar analyses were also performed using the OMERACT
definition of DAS28 minimal disease activity
4 and DAS28
European League Against Rheumatism (EULAR) good/moderate
responders
1 (supplemental table 1, available online only). The
results for DAS28 minimal disease activity were comparable to
those observed for MDAS and the results observed for EULAR
good/moderate responders were similar to those observed for
LDAS.
Onset of action
Table 2 presents the overall percentage success rate, NNS and
positive LR values for the onset of an ACR50 response compared
with achievement of an LDAS according to discriminatory
capacity or their ability to reflect inhibition of radiographic
progression or patient satisfaction. Analysis of the impact of
onset on ACR20 and ACR70 and MDAS and remission is
presented in supplemental table 2 (available online only).
For discriminatory capacity, the NNS was lowest when the
first ACR50 response occurred any time during the 6-month
period compared with occurrence in the first month; a similar
trend was observed for LDAS (table 2).
For structural damage progression at year 1, positive LR were
less than 2.05 for ACR50 and LDAS (table 2) criteria and were
comparable regardless of when the first response was achieved.
For patient satisfaction with treatment, positive LR for time
to onset of ACR50 was approximately 4 or more for all onset
time points explored and there was a trend towards an increased
positive LR with earlier onset (table 2). An earlier onset of
action was an important factor in the ability of LDAS to reflect
patient satisfaction (table 2). The positive LR of greater than 5
for onset of ACR50 or LDAS in the first 1 or 2 months suggests
not only prognostic, but also strong diagnostic evidence
(table 2).
14
Further analyses were performed on the subgroup of patients
who achieved an ACR20 or LDAS, examining the impact of
whether achievement of this response/status within the first
3 months reflected radiographic progression or patient satisfac-
tion: positive LR were less than 2 for both ACR20 and LDAS
(supplemental table 3, available online only).
Sustainability of response or disease status
Table 3 presents the overall percentage success rate, NNS and
positive LR values for sustainability of ACR50 versus LDAS
according to discriminatory capacity, inhibition of radiographic
progression and patient satisfaction. As expected, the overall
response rate for ACR50 and LDAS progressively decreased with
increasing numbers of required consecutive visits.
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six consecutive visits compared with one or more consecutive
visits (table 3).
For inhibition of structural progression, positive LR was less
than 2 for all ACR50 methods of reporting, regardless of how
long the response was maintained (table 3). For LDAS, there
was a slight trend towards better reflection of inhibition of
structural damage (TS ,0) with increasing sustainability of
response. Sustainability for three or more consecutive visits
demonstrated positive LR of 2 or greater (table 3).
Sustainability was an important factor in the ability to reflect
patient treatment satisfaction for both ACR50 and LDAS
(table 3). LR increased progressively with both sustainability
of ACR50 and LDAS.
Analysis of the impact of sustainability on ACR20 and
ACR70 and MDAS and remission is presented in supplemental
table 4 (available online only).
DISCUSSION
This exploratory analysis of data from the AIM trial strongly
supports the concept that the performance of different methods
of reporting ACR or DAS28-based criteria is dependent on the
desired outcome (eg, a better discriminatory capacity, inhibition
of radiographic progression or patient satisfaction with treat-
ment). This is the first study to evaluate the performance of
some of these methods in relation to outcomes deemed to
reflect the perspectives of the clinical trialist, rheumatologist
and patient.
From the perspective of researchers designing clinical trials to
test the efficacy and safety of new compounds (eg, phase II
trials), our data suggest that the ‘‘less stringent’’ ACR20 and
MDAS criteria assessed at the end of the trial achieved the
highest discriminatory capacity, allowing detection of a treat-
ment effect using fewer patients. When onset of action and
sustainability were considered, an increase was observed in the
NNS required to detect a treatment effect, suggesting that
when designing clinical trials, it may not be beneficial to take
these aspects into account for ACR and DAS28-based criteria.
For the criteria examined in this analysis, sustainability of
good disease status (LDAS) for 3 months or more during the
first 6 months of the study was the only method of reporting
that reflected the absence of radiographic progression at year 1
(using the positive LR cut-off of 2). Previously reported data
support this finding. In a longitudinal study including patients
who were followed for up to 9 years, fluctuations in disease
activity (compared with sustained LDAS or high DAS) were
predictive of more severe radiographic progression.
15 All other
techniques of reporting assessed here were poor predictors of the
inhibition of radiographic progression.
The methods that best reflected patient satisfaction with
treatment were ‘‘stringent’’ reporting techniques for both
response to treatment (ACR70) and status of disease (DAS28-
defined remission). A faster onset (within the first 3 months)
and the sustainability of a response/status of disease were
important factors in the ability to reflect patient satisfaction.
These results would be expected on the basis that a relatively
early and sustainable improvement in terms of symptoms, pain,
disability and fatigue is likely to be a primary concern for the
patient in terms of treatment outcome and quality of life.
16 17
These findings highlight the importance of the onset and
sustainability of a treatment response or disease activity status
and support recent EULAR/ACR recommendations that pro-
pose that the reporting of clinical trials should include both the
time to onset and the sustainability of the primary outcome.
18 19
Interpretation of our findings should be made in the context
of the study limitations. Results were obtained in an
exploratory analysis of a single clinical trial evaluating a single
compound (abatacept); before proposing firm recommenda-
tions, similar analyses should be conducted on data from
different trials evaluating alternative compounds. Moreover,
similar assessments using other criteria, such as LDAS by
DAS28 (using the erythrocyte sedimentation rate) or by the
simplified disease activity index or the clinical disease activity
index need to be evaluated. For most of the analyses, the
observed values of positive LR were not conclusive as the values
were below 10 or even 5, the thresholds often used to reflect a
‘‘relevant’’ value for diagnostic purposes.
14 However, a clear,
accepted definition of relevant positive LR thresholds does not
exist. For example, in the case of evaluation of the risk of toxic
events while taking non-steroidal anti-inflammatory drugs, a
positive LR value of 1.4 has been considered unacceptable.
20
Conversely, other studies, including one evaluating the ability
to predict persistent (erosive) arthritis, have demonstrated that
positive LR values of more than 2 may be considered a relevant
prognostic value,
21 22 whereas more than 10 is considered a
diagnostic value.
12
Finally, the relatively short duration of follow-up presented
here could impact the results. Observations were limited to this
time period because the number of patients achieving the more
stringent criteria (eg, ACR70 or remission), or onset or
sustainability at later time points, was too low to make valid
comparisons. However, as most clinicians would expect to
observe a treatment effect within 6 months of therapy
initiation, this time frame is probably an acceptable period
of assessment.
Considering these limitations, our analyses demonstrate that
the optimal method of assessment can depend on the outcome
of interest, and that onset and sustainability of success may be
important factors to consider when assessing the efficacy of
therapies for patients with RA. A potential ‘‘optimal’’ technique
could be the life-table analyses technique, in which the event is
defined by the time taken to reach an acceptable sustained
status. Future studies are required to confirm and extend the
findings presented here using other RA patient databases, longer
study durations and similar analyses in other disease areas.
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